Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
49 hedge funds and large institutions have $42.5M invested in Cidara Therapeutics in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 19 reducing their positions, and 3 closing their positions.
3% more capital invested
Capital invested by funds: $41.5M → $42.5M (+$1.08M)
0% more funds holding
Funds holding: 49 → 49 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.3% less ownership
Funds ownership: 3.18% → 2.89% (-0.3%)
58% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$276K |
| 2 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
+$225K |
| 3 |
Renaissance Technologies
New York
|
+$220K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$82.2K |
| 5 |
Bank of New York Mellon
New York
|
+$54.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$3.27M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$548K |
| 3 |
Invesco
Atlanta,
Georgia
|
-$356K |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$342K |
| 5 |
JP Morgan Chase
New York
|
-$198K |
CDTX Hedge Fund Activity: Q1 2019 in Review
49 of the 4,632 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q1 2019, worth a combined $42.5M — up 2.6% from $41.5M a quarter earlier.
Fund positioning in CDTX was balanced in Q1 2019: 3 funds opened new positions, 3 closed out, 8 added to existing stakes and 19 trimmed.
The largest buyer was Vanguard Group, adding an estimated $276K. The largest seller was BVF Inc, cutting an estimated $3.27M.
- 49 institutional investors held Cidara Therapeutics (CDTX) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $42.5M of Cidara Therapeutics stock for Q1 2019, up 2.6% quarter-over-quarter.
- 3 funds opened new Cidara Therapeutics positions in Q1 2019 and 3 closed out, a net change of 0 holders.
- The largest Cidara Therapeutics buyer in Q1 2019 was Vanguard Group, an estimated $276K added.
- The largest Cidara Therapeutics seller in Q1 2019 was BVF Inc, an estimated $3.27M sold.
Based on aggregated 13F filings for Q1 2019.